文献速递鼻科

美国变应性鼻炎当代增量医疗成本分析

Contemporary Incremental Healthcare Costs for Allergic Rhinitis in the United States.
PubMed 文献 · Laryngoscope · 2021-09-02

该研究基于2018年医疗支出面板调查的横截面分析,比较变应性鼻炎(AR)患者与非AR患者的医疗利用和成本,并与2007年数据对比。

核心结论

  • 过去十年正式就诊的AR患者显著减少,且与AR诊断相关的人均医疗支出也显著下降。
  • 鼻用糖皮质激素转为非处方药可能是这些变化的关键驱动因素。

研究设计与样本

  • 横截面分析,从2018年医疗支出面板调查中提取报告AR诊断的患者并链接 consolidated expenditures 文件。
  • 将AR患者与非AR患者比较,并使用人口学和合并症调整的多变量模型计算成本差异,结果与2007年数据对比。

主要发现

  • 与2007年不同,2018年AR患者人均年总医疗支出与非AR患者无差异。

临床怎么用

  • 临床应关注AR患者正式就诊率下降及鼻用糖皮质激素非处方化对医疗利用和成本的影响。

局限性

  • 证据等级为3。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: Describe contemporary changes in healthcare expenditure and utilization associated with allergic rhinitis (AR) over the past decade. STUDY DESIGN: Cross-sectional analysis. METHODS: Patients reporting a diagnosis of AR were extracted from the 2018 Medical Expenditure Panel Survey and linked to the consolidated expenditures file. AR patients were then compared to non-AR patients to demonstrate differences in healthcare utilization for office visits, emergency facility visits, and prescriptions. In addition, differences in total healthcare costs, office-based costs, and prescription costs were calculated, using demographic- and comorbidity-adjusted multivariate models. Results were compared to those obtained in 2007. RESULTS: In 2018, an estimated 1.94 ± 0.2 million adult patients reported AR (0.8% of the US population receiving medical care), a 90% decrease from the 17.8 ± 0.7 million patients seen in a formal healthcare setting for AR in 2007 (7.9%). AR patients still formally seen in 2018 had an average of 4.4 ± 1.3 more office visits (P = .001) and 9.7 ± 2.2 more prescription fills (P < .001) than non-AR patients. In contrast to the 2007 findings, there was no difference in total health care expenditure per person with AR per year. When comparing total healthcare expenditure between 2018 and 2007, there was a net decrease of $1,176 per person with AR per year (P < .01). CONCLUSIONS: Patients reporting AR in a formal healthcare encounter fell significantly over the past decade, and per-person expenditure associated with an AR diagnosis also decreased significantly. The transition of nasal corticosteroids to over-the-counter was potentially a key driver behind these changes. LEVEL OF EVIDENCE: 3 Laryngoscope, 132:1510-1514, 2022.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Workman AD, Dattilo L, Rathi VK, et al. Contemporary Incremental Healthcare Costs for Allergic Rhinitis in the United States. Laryngoscope. 2021. PMID: 34473353. doi:10.1002/lary.29846

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。